Copyright
©The Author(s) 2024.
World J Clin Cases. Jan 6, 2024; 12(1): 68-75
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.68
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.68
Table 2 Response rates in the two groups
| Group | Number of patients | Significant | Effective | Ineffective | Total efficacy rate |
| Observation group | 33 | 22 (66.66) | 9 (27.27) | 2 (6.06) | 31 (93.93) |
| Control group | 32 | 7 (21.87) | 15 (46.87) | 10 (31.25) | 22 (68.75) |
| χ2 | - | - | - | - | 6.847 |
| P value | - | - | - | - | 0.008 |
- Citation: Liu K, Li ZH. Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure. World J Clin Cases 2024; 12(1): 68-75
- URL: https://www.wjgnet.com/2307-8960/full/v12/i1/68.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i1.68